Curated News
By: NewsRamp Editorial Staff
October 26, 2026
Tonix Pharmaceuticals Sets Q3 2026 Earnings Call for Nov. 9
TLDR
- Tonix Pharmaceuticals will report Q3 2026 results on Nov. 9, giving investors an early edge on TNXP performance and pipeline progress.
- Tonix will host a conference call and webcast on Nov. 9, 2026, at 8:30 a.m. ET to report Q3 2026 financial results.
- Tonix advances treatments for fibromyalgia, depression, and rare diseases, aiming to improve lives for patients with high unmet medical needs.
- Tonix's TONMYA is the first new fibromyalgia treatment in over 15 years and is now being tested for major depressive disorder.
Impact - Why it Matters
Tonix’s upcoming earnings call provides investors with a timely update on the company’s financial health and operational progress, particularly as it commercializes TONMYA, the first new fibromyalgia treatment in over 15 years. The call may also shed light on the advancement of Tonix’s broader CNS and immunology pipelines, including Phase 2 programs for major depressive disorder and acute stress disorder, as well as TNX-2900 for Prader-Willi syndrome and TNX-1500 for kidney transplant rejection. For patients and healthcare providers, continued progress on these programs could eventually expand treatment options in areas of high unmet need. The announcement also underscores the role of NetworkNewsWire and IBN in disseminating critical financial information to the investment community, ensuring that stakeholders have access to timely updates.
Summary
Tonix Pharmaceuticals (NASDAQ: TNXP), a fully integrated, commercial-stage biotechnology company, has announced it will host a conference call and webcast on Monday, Nov. 9, 2026, at 8:30 a.m. ET to report its third-quarter 2026 financial results and operational highlights. Investors and interested parties can register to participate in the call or view the webcast through the company, with a replay available under “IR Events” in the Investors section of the Tonix website. For full details, the complete press release can be accessed at https://nnw.fm/va44Q.
Tonix Pharmaceuticals is focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. Its recently approved flagship medicine, TONMYA™ (cyclobenzaprine HCl sublingual tablets 2.8mg), is the first new treatment for fibromyalgia in more than 15 years. Tonix’s CNS commercial infrastructure supports its marketed products, including acute migraine products Zembrace® SymTouch® and Tosymra®. The company is also maximizing the science behind TONMYA in Phase 2 clinical trials for major depressive disorder and acute stress disorder, and its CNS portfolio includes TNX-2900, which is Phase 2 ready for Prader-Willi syndrome. Additionally, Tonix is advancing immunology programs such as TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for preventing kidney transplant rejection. The company notes that its product development candidates are investigational and have not been approved for any indication.
The latest news and updates relating to TNXP are available in the company’s newsroom at https://nnw.fm/TNXP. The announcement was distributed through NetworkNewsWire, a specialized communications platform focused on financial news and content distribution. NNW is part of the Dynamic Brand Portfolio @ IBN, which offers wire solutions via InvestorWire, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and corporate communications solutions.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Tonix Pharmaceuticals Sets Q3 2026 Earnings Call for Nov. 9
